| pubmed-article:18665167 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C2607850 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0205156 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0995188 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0205132 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0585332 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:18665167 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18665167 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18665167 | pubmed:dateCreated | 2008-8-5 | lld:pubmed |
| pubmed-article:18665167 | pubmed:abstractText | This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005 and November 2007 with irinotecan 180 mg m-2 and cetuximab 500 mg m-2 q2w (every 2 weeks), in every 21-day cycles, until unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The toxicity compared very favourably to weekly cetuximab combination schedules. Grade 3/4 adverse effects were observed in 12 patients. Overall, our results turn up very similar both in terms of toxicity and efficacy to those obtained by weekly and biweekly administration regimens. | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18665167 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18665167 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18665167 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18665167 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18665167 | pubmed:issn | 1532-1827 | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:BoschAA | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:CervantesAA | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:RosellóSS | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:ChirivellaII | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:Rodríguez-Bra... | lld:pubmed |
| pubmed-article:18665167 | pubmed:author | pubmed-author:Martín-Martor... | lld:pubmed |
| pubmed-article:18665167 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18665167 | pubmed:day | 5 | lld:pubmed |
| pubmed-article:18665167 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:18665167 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18665167 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18665167 | pubmed:pagination | 455-8 | lld:pubmed |
| pubmed-article:18665167 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:meshHeading | pubmed-meshheading:18665167... | lld:pubmed |
| pubmed-article:18665167 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18665167 | pubmed:articleTitle | Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. | lld:pubmed |
| pubmed-article:18665167 | pubmed:affiliation | Department of Haematology and Medical Oncology, Hospital Clínico Universitario, University of Valencia, Valencia, Spain. | lld:pubmed |
| pubmed-article:18665167 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18665167 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18665167 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18665167 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18665167 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18665167 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18665167 | lld:pubmed |
